CEO Total Pay
$6.3M
FY2022 Summary Compensation, below median
TBPH FY2022 SEC EDGAR DEF 14A
Theravance Biopharma, Inc. CEO pay ratio
The CEO earned $6.3M in FY2022 against median worker pay of $247,108 · Chemicals & Pharmaceuticals.
- State
- CA
- Filing date
- 2023-03-28
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2022
Data updated August 2026
Subscribe to Theravance Biopharma, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
25:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.3M
Median worker
$247,108
Latest filing FY2022. This company's newest DEF 14A on file is for FY2022, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Theravance Biopharma, Inc. reported a 25:1 CEO-to-worker pay ratio in FY2022 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 25:1
- FY2022 disclosed
- CEO total
- $6.3M
- Summary Compensation Table total
- Median worker
- $247,108
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2022
A component-level pay breakdown is not reported in Theravance Biopharma, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Theravance Biopharma, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2022. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 25:1
- FY2022
- vs prior FY
- +15:1
- from FY2021 10:1
- CEO $ YoY
- +41%
- $6.3M latest
- Filings shown
- 2
- FY2021–2022
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $4.5M | - | $440,558 | 10:1 | - |
| 2022 | $6.3M | +41% | $247,108 | 25:1 | +15:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1583107, FY2021–2022. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
25:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.3M
Companies in Industry
168
vs. Industry Median
Below
Theravance Biopharma, Inc.: MODEST · HEAVY pay ratio
Theravance Biopharma, Inc. disclosed 25:1 CEO-to-worker pay and $6.3M CEO total in FY2022. the CEO earned 25× the median employee ($247,108) in FY2022.
Median employee $247,108 (ELITE-MED); MODEST · HEAVY stamps put about 25 median-wage years per CEO year.
Pay Ratio
25:1
Below typical
What FY2022 shows for Theravance Biopharma, Inc.
Theravance Biopharma, Inc. disclosed 25:1 CEO-to-worker pay and $6.3M CEO total in FY2022. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Theravance Biopharma, Inc.'s $6.3M CEO total is at or below the $7.9M industry median CEO pay.
Theravance Biopharma, Inc. stamps MODEST · HEAVY · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2022
- Total Compensation
- $6.3M
- Median Employee Pay
- $247,108
- Pay Ratio
- 25:1
- Filing Date
- 2023-03-28
Company Info
- Ticker
- TBPH
- CIK
- 1583107
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- CA
SEC EDGAR DEF 14A for CIK 1583107, FY2022. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Theravance Biopharma, Inc. disclosed 25:1 CEO-to-worker pay and $6.3M CEO total in FY2022.
Read with Theravance Biopharma, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.
TrueBlue, Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.3M (Δ $899 lighter vs Theravance Biopharma, Inc.); EXTREME · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Upbound Group, Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.3M (Δ $7K heavier vs Theravance Biopharma, Inc.); STEEP · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Avangrid, Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.3M (Δ $8K heavier vs Theravance Biopharma, Inc.); MODEST · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Maximus, Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.3M (Δ $9K heavier vs Theravance Biopharma, Inc.); STEEP · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Theravance Biopharma, Inc. stamps MODEST · HEAVY · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MODEST
See where MODEST · HEAVY packages sit on the national leaderboard after reading Theravance Biopharma, Inc..
Ratio primer · MODEST
Theravance Biopharma, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Theravance Biopharma, Inc. (CIK 1583107), FY2022. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.